NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Editas Medicine, Inc. (EDIT) Stock Analysis

Editas Medicine, Inc. (EDIT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

EDIT

$2.51

−$0.07 (−2.71%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare EDIT with… →

EDIT Key Statistics

As of Oct 21, 2026
Trading
Open
$2.59
Previous Close
$2.58
Day's Range
2.50–2.60
52-Week Range
1.66–3.94
Volume
1.14M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.00
Valuation
Market Cap
$385.49M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
8.20
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.68
Financials (FY)
Revenue (FY)
$40.52M+25.39%
Net Income (FY)
−$160.06M
Profit marginThe share of revenue left as profit after all costs and taxes.
−157.32%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
153.58M
1-Year Return
−35.31%
Dividend and dates
Earnings Date
November 9, 2026estimated
Avg Volume
2.55M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, EDIT closed at $2.51, −35.31% over 1 year.

Editas Medicine, Inc. (EDIT) has a market capitalization of $385.49M.

In fiscal 2025, EDIT reported revenue of $40.52M.

EDIT Stock Return by Calendar Year

Editas Medicine, Inc. (EDIT) 10-year return: what $10,000 became

1 year
$10,000 $6,469
−35.31%
5 years
$10,000 $652
−93.48%
10 years
$10,000 $1,638
−83.62%

If you had invested $10,000 in Editas Medicine, Inc. (EDIT) 10 years ago, at the close on October 21, 2016, it would have been worth $1,638 at the close on October 21, 2026: −83.62% in total, −16.55% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+22.44%
2025+61.42%
2024−87.46%
2023+14.21%
2022−66.59%
2021−62.13%
2020+136.78%
2019+30.15%
2018−25.97%
2017+89.34%
2016 (partial year)−31.52%

As of October 21, 2026.

EDIT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$40.52M−$160.06M−395.0%
2024$32.31M−$237.09M−733.7%
2023$78.12M−$153.22M−196.1%
2022$19.71M−$220.43M−1,118.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$40.52M—−$99.34M−$160.06M−395.0%
2024$32.31M—−$238.92M−$237.09M−733.7%
2023$78.12M—−$169.18M−$153.22M−196.1%
2022$19.71M—−$225.95M−$220.43M−1,118.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

EDIT Valuation vs Biotechnology Median

Median of 608 stocks
MetricEDITBiotechnology medianvs median
P/S ratio8.2013.3038% below
Profit margin−157.32%−38.31%119.0 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Editas Medicine, Inc. (EDIT) is capitalised at $385.49M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 87 employees.

The most recent close on file for EDIT is $2.51, dated October 21, 2026. That is −$0.07 (−2.71%) against the previous close. Over the past 52 weeks the price has ranged from $1.66 to $3.94. The latest close sits 51.2% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $40.52M. That is +25.39% against the prior fiscal year, when revenue was $32.31M. The same year closed with a net loss of $160.06M. Profit margin runs at −157.32%. That is 119 percentage points below the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to −0.68.

Across the 4 fiscal years on file, revenue moves from $19.71M in 2022 to $40.52M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 8.2 times revenue. On price-to-sales that is 38.33% below the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The reported beta is 2. Annualized volatility over the trailing 10 years is 84.26%. Over the trailing twelve months the total return is −35.31%. Measured over 10 years, that is −16.55% a year compounded.

Growth & Income

The record shows no dividend for EDIT.

The strongest complete calendar year on file is 2020 at +136.78%; the weakest is 2024 at −87.46%. Of the 9 complete calendar years on file, 5 finished higher. 2026 is still running; the total return is +22.44% year to date.

Peer Comparison

Editas Medicine, Inc. (EDIT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Editas Medicine, Inc. EDIT $385.49M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Editas Medicine, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Editas Medicine, Inc.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Visit website →